Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) recently held a special meeting to deploy the implementation of the DeepSeek R1 large model, chaired by Chairman Zhang Yufu. The company aims to accelerate the development and commercialization of the SPT-07A project through AI technology, marking a significant step in its “Knowledge Transformation, Innovation Development” strategy.
AI in Drug Research and Development
DeepSeek R1 will revolutionize drug research and development at Tonghua Golden-Horse by optimizing target identification and validation, compound design, and clinical trial design. This AI model will integrate vast amounts of biomedical and clinical data to accelerate research breakthroughs and resource allocation in innovation drug development.
AI-Enabled Traditional Chinese Medicine Innovation
As a leader in traditional Chinese medicine modernization, Tonghua Golden-Horse will use DeepSeek R1 to analyze the active components of musk and develop new, effective substances. The AI will simulate the pharmacological mechanisms of musk components, providing scientific evidence for improving traditional formulas.
Commercial Model Innovation
The company will transition from a traditional pharmaceutical supplier to a health value network operator by leveraging AI to redefine connections with doctors, patients, and payers. This shift will create a new paradigm in the pharmaceutical commercial ecosystem, driven by data flow and shared value.
Collaboration with AI Vendors
Tonghua Golden-Horse plans to collaborate with leading AI companies to develop customized solutions and enhance AI capabilities across all business functions. These collaborations will focus on digital transformation, intelligent decision-making, and innovative business models.
Conclusion
The deployment of DeepSeek R1 represents a milestone in Tonghua Golden-Horse’s strategic transformation. By embracing AI technology, the company aims to become a benchmark for AI application in the pharmaceutical industry and contribute to the high-quality development of China’s healthcare sector.-Fineline Info & Tech
AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio
AstraZeneca Licenses Alteogen's ALT-B4 for Subcutaneous Cancer Therapies
Merck & Co.'s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment
ROBO Medical's Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval
Leave a Reply